BCC Research
View Existing Reports | Report Subscriptions | Upcoming Reports | Press Room
 

Pharmaceuticals

Therapies for Depressive and Anxiety Disorders  

Report Code: PHM056A, Published: February 2010


 

THIS REPORT:

  • Analyzes the current global markets for depressive and anxiety disorder treatments, with data for 2008, estimates for 2009, and projections, with compound annual growth rates (CAGRs), through 2014
  • Identifies the number of people globally diagnosed with depressive and anxiety disorders
  • Examines the markets for Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), tricyclic antidepressants, and other drugs used to treat depressive and anxiety disorders
  • Covers the market potential for novel antidepressants, including triple update inhibitors, and their mechanisms of action
  • Describes regulatory and economic issues
  • Reviews the industry and its structure, and the many companies involved in providing depressive and anxiety disorder medications.

Report Code: PHM056A, Published: February 2010, Analyst: Mary Anne Crandall

 
 

   Bookmark and Share


   


All transactions on our web site are conducted on a Secure SSL Server.
Copyright 2010 © All rights reserved.   About Us | Contact Us | Careers | Privacy Policy  |  Site Map |  XML Map